CROI 2017 Program and Information

Program and Agenda

754 SUBSTANTIALLY LOWER RILPIVIRINE PLASMA CONCENTRATIONS DURING PREGNANCY

Angela Colbers 1 , Stein Schalkwijk 1 , Deborah Konopnicki 2 , Andrea Gingelmaier 3 , John Lambert 4 , Ineke van der Ende 5 , José Moltó 6 , David M. Burger 1 , for the PANNA Network 1 Radboud Univ Med Cntr, Nijmegen, Netherlands, 2 Saint-Pierre Univ Hosp, Brussels, Belgium, 3 Klinikum der Univ München, München, Germany, 4 Mater Misericordiae Univ Hosp Dublin, Dublin, Ireland, 5 Erasmus Univ Med Cntr, Rotterdam, Netherlands, 6 Fundació Lluita Contra la Sida, Badalona, Spain 755 ELVITEGRAVIR/COBICISTAT PHARMACOKINETICS INPREGNANCY AND POSTPARTUM Brookie Best 1 , Edmund Capparelli 1 , Alice Stek 2 , Edward Acosta 3 , Elizabeth Smith 4 , Nahida Chakhtoura 5 , Jiajia Wang 6 , Adriane Hernandez 7 , Mark Mirochnick 8 , for the IMPAACT P1026s Protocol Team 1 Univ of California San Diego, La Jolla, CA, USA, 2 Univ of Southern California, Los Angeles, CA, USA, 3 Univ of Alabama at Birmingham, Birmingham, AL, USA, 4 DAIDS, NIAID, Rockville, MD, USA, 5 NICHD, Bethesda, MD, USA, 6 Harvard Univ, Boston, MA, USA, 7 Frontier Sci & Tech Rsr, Amherst, NY, USA, 8 Boston Med Cntr, Boston, MA, USA 756 PROTEASE-INHIBITOR–BASED CART IS ASSOCIATEDWITHHIGH ESTRADIOL LEVELS IN PREGNANCY Kayode Balogun 1 , Monica Guzman 1 , Eszter Papp 1 , Mona Loutfy 2 , Mark Yudin 3 , Jay MacGillivray 4 , Kellie Murphy 5 , Sharon Walmsley 6 , Michael Silverman 6 , Lena Serghides 1 1 Univ Hlth Network, Toronto, Ontario, Canada, 2 Women’s Coll Rsr Inst, Toronto, Ontario, Canada, 3 St. Michael’s Hosp, Toronto, Ontario, Canada, 4 Mt Sinai Hosp, Toronto, Ontario, Canada, 5 Univ of Toronto, Toronto, Ontario, Canada, 6 Univ of Western Ontario, London, Ontario, Canada 757 RALTEGRAVIR PHARMACOKINETICS AND SAFETY INHIV-1 EXPOSED NEONATES: DOSE-FINDING STUDY Diana F. Clarke 1 , Edward Acosta 2 , Anne Chain 3 , Mae Cababasay 4 , Jiajia Wang 5 , Hedy Teppler 6 , Elizabeth Smith 7 , Rohan Hazra 8 , Mark Mirochnick 8 , for the IMPAACT P1110 Protocol Team 1 Boston Med Cntr, Boston, MA, USA, 2 Univ of Alabama at Birmingham, Birmingham, AL, USA, 3 Merck Rsr Labs, Rahway, NJ, USA, 4 Harvard Univ, Boston, MA, USA, 5 Merck Rsr Labs, North Wales, PA, USA, 6 DAIDS, NIAID, Rockville, MD, USA, 7 NICHD, Bethesda, MD, USA, 8 Boston Univ, Boston, MA, USA 758 PHARMACOKINETICS OF NEVIRAPINE PROPHYLAXIS INHIV- EXPOSED LOWBIRTHWEIGHT INFANTS Adrie Bekker 1 , Avy Violari 2 , Mae Cababasay 3 , Jiajia Wang 3 , Lubbe Wiesner 4 , Edmund Capparelli 5 , Mark Cotton 1 , Firdose Nakwa 2 , Mark Mirochnick 6 , for the IMPAACT P1106 Team 1 Stellenbosch Univ, Cape Town, South Africa, 2 Univ of Witwatersrand, Johannesburg, South Africa, 3 Harvard Univ, Boston, MA, USA, 4 Univ of Cape Town, Cape Town, South Africa, 5 Univ of California San Diego, La Jolla, CA, USA, 6 Boston Med Cntr, Boston, MA, USA

Poster Sessions • Thursday

CROI 2017 195